Moreover, CLL-1 may be included in a single-tube approach to evaluate CD34 + CD38- leukemic stem cells, which is a procedure that the European LeukemiaNet (ELN) AML MRD 2021 consensus supports [9]. The gene discussed is CD38; the disease is acute myeloid leukemia.